Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19144912 | 0.87 | IDO1 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14090989 | 0.83 | SLC6A4 (0.71) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7416190 | 0.83 | SLC6A4 (0.49) | SLC6A4 | |
| SCHEMBL12066334 | 0.81 | IDO1 (0.68) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL20524613 | 0.81 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3895104 | 0.81 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL15793901 | 0.80 | SLC6A4 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27462153 | 0.78 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12156358 | 0.78 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14962110 | 0.78 | SLC6A2 (0.84) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| WO-2003068807-A2 | ECHINOCANDIN CYCLIC PEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | NGLY1, ARG1, ERG28 | SLC6A2 4884/4885SLC6A4 4883/4885SLC6A3 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.